



BRIAN SANDOVAL
Governor

STATE OF NEVADA
DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 E. William Street, Suite 101
Carson City, Nevada 89701
www.dhcfp.nv.gov

MICHAEL J. WILLDEN
Director

CHARLES DUARTE
Administrator

NOTICE OF OPEN PUBLIC MEETING

The Division of Health Care Financing and Policy (DHCFP) Pharmacy and Therapeutics Committee will conduct a public meeting on **September 27, 2012**, beginning at **1:00 p.m.** at the following location:

**Nevada State Health Division
3811 W. Charleston Blvd, Suite 112
Las Vegas, NV 89102**

Some members will be attending the meeting via video conference at Nevada State Health Division, 4150 Technology Way, Suite 300, Carson City, Nevada 89506 (public seating is limited).

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Rita Mackie at: 775-684-3681 or email rmackie@dhcfp.nv.gov in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Items may be taken out of order.

Items may be combined for consideration by the public body.

Items may be pulled or removed from the agenda at any time.

Public comment is limited to 5 minutes per individual, organization, or agency, but may be extended at the discretion of the Chairperson.

AGENDA

I. Call to Order and Roll Call

II. Public Comment

No action may be taken on a matter raised under this item of the agenda until the matter itself has been specifically included on the agenda as an item upon which action can be taken.

III. **For Possible Action:** Review and Approval of the March 22, 2012 and June 28, 2012 Meeting Minutes

IV. Status Update by DHCFP

- A. Public Comment
- B. Program Updates

V. Established Drug Classes

A. Acne Agents: Topical, Benzoyl Peroxide, Antibiotics and Combination Products

- 1. Public Comment
- 2. Drug Class Review Presentation – SXC Health Solutions
- 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
- 5. **For Possible Action:** Committee Discussion and Approval of Drugs for inclusion on the PDL

B. Analgesics/Anesthetics: Topical

- 1. Public Comment
- 2. Drug Class Review Presentation – SXC Health Solutions
- 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
- 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

C. Antibiotics: Cephalosporin 3rd Generation

- 1. Public Comment
- 2. Drug Class Review Presentation – SXC Health Solutions
- 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
- 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

D. Anticoagulants: Oral

- 1. Public Comment
- 2. Drug Class Review Presentation – SXC Health Solutions
- 3. **For Possible Action:** Committee Discussion and Action

- a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
 - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for inclusion on the PDL

- E. Antipsychotics: Atypical
 - 1. Public Comment
 - 2. Drug Class Review Presentation – SXC Health Solutions
 - 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
 - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- F. Antivirals: Hepatitis C Protease Inhibitors
 - 1. Public Comment
 - 2. Drug Class Review Presentation – SXC Health Solutions
 - 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
 - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- G. Cardiovascular: Antihyperlipidemics, Statins and Statin Combinations
 - 1. Public Comment
 - 2. Drug Class Review Presentation – SXC Health Solutions
 - 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
 - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- H. Central Nervous System: ADHD/Stimulants
 - 1. Public Comment
 - 2. Drug Class Review Presentation – SXC Health Solutions

3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- I. Electrolyte Depleters
1. Public Comment
 2. Drug Class Review Presentation – SXC Health Solutions
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- J. Gastrointestinal Agents: Proton Pump Inhibitors
1. Public Comment
 2. Drug Class Review Presentation – SXC Health Solutions
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- K. Growth Hormone Agents
1. Public Comment
 2. Drug Class Review Presentation – SXC Health Solutions
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- L. Immunomodulators: Injectable
1. Public Comment

2. Drug Class Review Presentation – SXC Health Solutions
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

M. Ophthalmic Quinolones

1. Public Comment
2. Drug Class Review Presentation – SXC Health Solutions
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

N. Respiratory: Inhaled Anticholinergic Agents

1. Public Comment
2. Drug Class Review Presentation – SXC Health Solutions
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

O. Respiratory: Short Acting Beta Adrenergics-Inhalers/Nebulizers

1. Public Comment
2. Drug Class Review Presentation – SXC Health Solutions
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- P. Cardiovascular: Antihyperlipidemics, Cholesterol Absorption Inhibitors
1. Public Comment
 2. Drug Class Review Presentation – SXC Health Solutions
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- Q. Pulmonary Arterial Hypertension Agents: Oral Agents
1. Public Comment
 2. Drug Class Review Presentation – SXC Health Solutions
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

VI. ANNUAL REVIEW-DRUG CLASSES BEING REVIEWED DUE TO RELEASE OF NEW DRUGS

- A. Analgesics: Tramadol and Related Drugs
1. Public Comment
 2. Drug Class Review Presentation – SXC Health Solutions
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for inclusion on the PDL
- B. Central Nervous System: Anticonvulsants, Misc
1. Public Comment
 2. Drug Class Review Presentation – SXC Health Solutions
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy

5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- C. Central Nervous System: Sedative Hypnotics
1. Public Comment
 2. Drug Class Review Presentation – SXC Health Solutions
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- D. Erythropoiesis Stimulating Proteins
1. Public Comment
 2. Drug Class Review Presentation – SXC Health Solutions
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- E. Gastrointestinal Agents: Pancreatic Enzymes
1. Public Comment
 2. Drug Class Review Presentation – SXC Health Solutions
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- F. Respiratory: Intranasal Steroids
1. Public Comment
 2. Drug Class Review Presentation – SXC Health Solutions
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups

4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- G. Urinary Tract Antispasmodics
1. Public Comment
 2. Drug Class Review Presentation – SXC Health Solutions
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

VII. ANNUAL REVIEW – Drug Classes Without Proposed Changes

- A. Public Comment
- B. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by SXC Health Solutions and the Division of Health Care Financing and Policy Without Changes
 1. Acne Agents: Topical, Retinoid Agents and Combinations
 2. Alzheimer's Agents
 3. Analgesics: Long Acting Narcotics
 4. Anaphylaxis: Self-Injectable Epinephrine
 5. Antibiotics: Cephalosporin 2nd Generation
 6. Antibiotics: Macrolides
 7. Antibiotics: Quinolones 2nd Generation
 8. Antibiotics: Quinolones 3rd Generation
 9. Anticoagulants: Injectable
 10. Antidepressants: SSRIs
 11. Antidepressants: Other
 12. Antiemetics: Oral, 5-HT₃
 13. Antifungals: Onychomycosis Agents
 14. Antihistamines: Second Generation
 15. Antihyperuricemics: Xanthine Oxidase Inhibitors for Gout
 16. Anti-Migraine Agents: Non-ergot Dopamine Agonists
 17. Antiparkinson's Agents: Non-ergot Dopamine Agonists
 18. Antivirals: Hepatitis C Non-Pegylated Interferons
 19. Antivirals: Hepatitis C Pegylated Interferons
 20. Antivirals: Hepatitis C Ribavirins
 21. Benign Prostatic Hyperplasia (BPH) Agents: 5-alpha-reductase Inhibitors

22. Benign Prostatic Hyperplasia (BPH) Agents: Alpha-blockers
23. Bone Ossification Agents: Bisphosphonates
24. Cardiovascular: ACE Inhibitors and Diuretic Combinations
25. Cardiovascular: Angiotensin II Receptor Blockers and Diuretic Combinations
26. Cardiovascular: Antihyperlipidemics, Bile Acid Sequestrants
27. Cardiovascular: Antihyperlipidemics, Cholesterol Absorption Inhibitors
28. Cardiovascular: Antihyperlipidemics, Niacin Agents
29. Cardiovascular: Beta Blockers
30. Cardiovascular: Calcium Channel Blockers and Combinations
31. Cardiovascular: Direct Renin Inhibitors and Combinations
32. Central Nervous System: Anticonvulsants, Barbiturates
33. Central Nervous System: Anticonvulsants, Hydantoins
34. Diabetic Agents: alpha-glucosidase inhibitor
35. Diabetic Agents: Amylin Analogs
36. Diabetic Agents: Biguanides
37. Diabetic Agents: Incretin Mimetics
38. Diabetic Agents: Insulin Products
39. Diabetic Agents: Meglitinides and Combinations
40. Diabetic Agents: Sulfonylureas
41. Diabetic Agents: Thiazolidinediones
42. Gastrointestinal Agents: H₂RA's
43. Gastrointestinal Agents: Ulcerative Colitis
44. Herpetic Antiviral Agents
45. Herpetic Antiviral Agents: Topical
46. Immunomodulators: Topical
47. Impetigo Agents: Topical
48. Leukotriene Modifiers
49. Multiple Sclerosis Agents: Disease Modifying
50. Multiple Sclerosis Agents: Specific Symptomatic Treatment
51. Nasal Calcitonins
52. Ophthalmic Antibiotics: Macrolides
53. Ophthalmic Antihistamines
54. Ophthalmic Non-steroidal anti-inflammatory agents
55. Ophthalmic Glaucoma Agents
56. Otic Fluoroquinolones
57. Progestins for Cachexia
58. Psoriasis Agents: Topical
59. Pulmonary Arterial Hypertension agents: Inhaled Agents
60. Respiratory: Oral COPD Agents
61. Respiratory: Inhaled Corticosteroids/Nebulizers
62. Respiratory: Long-Acting Beta Adrenergics
63. Skeletal Muscle Relaxants
64. Respiratory: Intranasal Antihistamines and Combinations

- 65. Cardiovascular: Antihyperlipidemics, Triglycerides Lowering Agents
- C. **For Possible Action:** Committee Discussion and Approval of Drug Classes Without Changes to the PDL
- VIII. Report by SXC on New Drugs to Market, New Generic Drugs to Market, and New Line Extensions
- IX. Review of Next Meeting Location, Date, and Time
- X. Public Comment
- XI. Adjournment

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site (www.dhcfp.nv.gov)

Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m., or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.

All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.

Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at both meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.